Loading...
 

July- September 2019: 

Volume 32, Issue 3

Click on the image to download the Issue in PDF format.

ARCHIVE

Pneumon 2019, 32(3):89-100, Review
New Antibiotics for Hospital-acquired pneumonia
Authors Information

Consultant in Respiratory Medicine, 6th Respiratory Department,
Sotiria Chest Diseases Hospital, Athens, Greece

Abstract

Introduction: Hospital-acquired pneumonia is the most common life-threatening hospital-acquired infection, and the majority of cases (80%) are associated with mechanical ventilation. Once pneumonia develops, the appropriateness of the initial antibiotic regimen is a vital determinant of outcome. Areas Covered: In this review we summarize the actual situation of new antibiotics for treatment of HAP and VAP. This article covers medical literature published in English language since 2000 until February 2019, on "hospital pneumonia", identified using PubMed and www.clinicaltrial.gov. The search terms used were "ventilator associated pneumonia", "resistance", "therapy" and "new antibiotics". Expert Opinion: Newer drugs approved for the combat of MDR pathogens for hospital pneumonia include cephalosporins active against MRSA and β-lactamases and as: ceftolozane combined with avibactam and ceftazidime with tazobactam. Other antibiotics active against ESBL are the combinations of carbapenems Cilastatin/imipenem/relebactam and meropenem/ Vaborbactam, plazomicin a semisynthetic derivative of sisomycin, and a new cephalosporine cefiderocol.